JSAM
J. Safra Asset Management Portfolio holdings
AUM
$1.38B
This Quarter Return
-3.03%
1 Year Return
+16.76%
3 Year Return
+74.03%
5 Year Return
+124.37%
10 Year Return
–
AUM
$1.2B
AUM Growth
+$1.2B
(-2.5%)
Cap. Flow
+$23M
Cap. Flow
% of AUM
1.91%
Top 10 Holdings %
Top 10 Hldgs %
69.55%
Holding
375
New
34
Increased
169
Reduced
54
Closed
70
Top Buys
| 1 |
iShares MSCI All Country Asia ex Japan ETF
AAXJ
|
$55.7M |
| 2 |
Listed Funds Trust Roundhill Magnificent Seven ETF
MAGS
|
$16.6M |
| 3 |
Invesco QQQ Trust
QQQ
|
$7.05M |
| 4 |
Technology Select Sector SPDR Fund
XLK
|
$3.31M |
| 5 |
iShares Russell 1000 Growth ETF
IWF
|
$2.77M |
Top Sells
| 1 |
iShares Core S&P Small-Cap ETF
IJR
|
$68.1M |
| 2 |
Vanguard S&P 500 ETF
VOO
|
$5.73M |
| 3 |
iShares Russell 1000 ETF
IWB
|
$3.56M |
| 4 |
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
|
$2.39M |
| 5 |
Health Care Select Sector SPDR Fund
XLV
|
$1.35M |
Sector Composition
| 1 | Technology | 1.85% |
| 2 | Communication Services | 0.85% |
| 3 | Consumer Discretionary | 0.71% |
| 4 | Financials | 0.61% |
| 5 | Healthcare | 0.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
251
Diodes
DIOD
$2.53B
| $10.2K | ﹤0.01% |
236
+73
| +45% | +$3.15K |
|
252
ePlus
PLUS
$1.93B
| $10.1K | ﹤0.01% |
166
+10
| +6% | +$610 |
|
253
Ecolab
ECL
$78.6B
| $9.63K | ﹤0.01% |
38
-400
| -91% | -$101K |
|
254
Bankunited
BKU
$2.95B
| $9.57K | ﹤0.01% |
278
+17
| +7% | +$585 |
|
255
Fair Isaac
FICO
$36.5B
| $9.22K | ﹤0.01% |
5
-5
| -50% | -$9.22K |
|
|
PENG
256
Penguin Solutions, Inc. Ordinary Shares
PENG
$1.26B
| $9.17K | ﹤0.01% |
528
+14
| +3% | +$243 |
|
257
ArcBest
ARCB
$1.68B
| $8.68K | ﹤0.01% |
123
+7
| +6% | +$494 |
|
258
Gartner
IT
$19B
| $7.56K | ﹤0.01% |
18
-20
| -53% | -$8.39K |
|
259
American Eagle Outfitters
AEO
$2.24B
| $6.79K | ﹤0.01% |
584
+24
| +4% | +$279 |
|
260
First Northwest Bancorp
FNWB
$66.2M
| $6.68K | ﹤0.01% |
657
+34
| +5% | +$345 |
|
261
Rocky Brands
RCKY
$227M
| $6.15K | ﹤0.01% |
354
+13
| +4% | +$226 |
|
262
Celldex Therapeutics
CLDX
$1.47B
| $5.99K | ﹤0.01% |
330
+18
| +6% | +$327 |
|
263
Caleres
CAL
$507M
| $5.48K | ﹤0.01% |
318
+14
| +5% | +$241 |
|
264
Penumbra
PEN
$10.6B
| $3.48K | ﹤0.01% |
13
| – | – |
|
265
Masimo
MASI
$7.59B
| $2.5K | ﹤0.01% |
15
| – | – |
|
266
Insulet
PODD
$23.9B
| $2.36K | ﹤0.01% |
9
| – | – |
|
267
Alnylam Pharmaceuticals
ALNY
$58.5B
| $1.89K | ﹤0.01% |
7
| – | – |
|
268
Stryker
SYK
$150B
| $1.49K | ﹤0.01% |
4
| – | – |
|
269
Exact Sciences
EXAS
$8.98B
| $1.34K | ﹤0.01% |
31
+10
| +48% | +$433 |
|
270
Veeva Systems
VEEV
$44B
| $1.16K | ﹤0.01% |
5
| – | – |
|
271
Privia Health
PRVA
$2.83B
| $1.1K | ﹤0.01% |
49
-11
| -18% | -$247 |
|
272
Gilead Sciences
GILD
$140B
| $1.01K | ﹤0.01% |
9
+5
| +125% | +$560 |
|
273
Alignment Healthcare
ALHC
$3.24B
| $950 | ﹤0.01% |
51
| – | – |
|
274
Legend Biotech
LEGN
$6.41B
| $950 | ﹤0.01% |
28
| – | – |
|
275
CVS Health
CVS
$92.8B
| $881 | ﹤0.01% |
13
-3,000
| -100% | -$203K |
|